

Contact:

Loraine V. Upham

Lori@CureDM.com

(505-515-1947)

CureDM Participates in 2017 RESI San Francisco

Wilmington, DE – January 09, 2017 – CureDM announces plans to participate in the 2017 Redefining Early Stage Investing (RESI) Conference in San Francisco on January 10. The conference is being held at the Marines Memorial Club and Hotel in conjunction with Johnson & Johnson. RESI is a one-day partnering event that enables early-stage life science, medtech and digital health companies to find and interact with potential investors and strategic partners.

CEO, Loraine Upham states, “We have quite a number of meetings lined up through the partnering system and we are excited to have the opportunity to network and share our strategic plans with investors and strategic partners from all over the world.” The company is actively engaged in fundraising, clinical development planning and partnering to bring forth a novel treatment approach to diabetes with their lead compound, HIP2B. HIP2B is a human derived peptide therapeutic that stimulates proteomic pathways that lead to islet neogenesis that can restore islet mass by creating new, healthy islets. Both type 1 and type 2 indications are being pursued.

About CureDM

CureDM is a biopharmaceutical company focused on the discovery and development of new therapeutics that prevent, ameliorate, or reverse diseases of metabolism. CureDM was co-founded by a molecular biologist and two endocrinologists who experienced the unmet medical need in diabetes patients on a daily basis, which provided the motivation for the discovery of HIP2B. For more information about CureDM, visit www.curedm.com.

XXXXXX